Increasing patient safety among multiple sclerosis drug dalfampridine users by expanding awareness of the serious side effects (3 January 2022)

Summary

This case report in the journal Cureus examines the use of dalfampridine, a drug used to improve walking in multiple sclerosis (MS) patients. Dalfampridine can have serious side effects including inducing seizures.

Although the US Food and Drug Administration (FDA) recommends stopping the medication permanently after a single seizure episode, this recommendation is not widely known by health care professionals. The authors argue that there is a need to raise awareness of the FDA recommendation and the potential for dalfampridine to cause seizures amongst primary and secondary care doctors and patients.